HomeLifestyleRetailCompany Overview: Synaptogenix (SNPX) - Possible New Alzheimer's Treatment
Company Overview: Synaptogenix (SNPX) - Possible New Alzheimer's Treatment

Synaptogenix (SNPX) is a clinical-stage biotechnology company that focuses on treating neurodegenerative diseases. Daniel Alkon, President and Chief Scientific Officer of Synaptogenix, discusses the development of a drug candidate called Bryostatin for the treatment of Alzheimer’s disease. He says that 94% of the patients who took the drug showed improvement in their cognitive function. He also talks about other restorative therapeutics Synaptogenix has in development as well as what’s next for the company.

The Watch List

25 Jun 2021

ON AIR
5:00 am
Next Gen Investing
replay
12:00 am
Fast Market
REPLAY
education
1:00 am
Your First Trade
REPLAY
1:30 am
Next Gen Investing
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Trading 360
REPLAY
4:00 am
Fast Market
REPLAY
ON AIR
5:00 am
Next Gen Investing
REPLAY
education
6:00 am
Your First Trade
REPLAY
6:30 am
Trading 360
REPLAY
7:30 am
Fast Market
REPLAY
8:30 am
Next Gen Investing
REPLAY
education
9:30 am
Your First Trade
REPLAY
10:00 am
Trading 360
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Your First Trade
REPLAY
1:30 pm
Trading 360
REPLAY
2:30 pm
Fast Market
REPLAY
3:30 pm
Next Gen Investing
REPLAY
education
4:30 pm
Your First Trade
REPLAY
5:00 pm
Trading 360
REPLAY
6:00 pm
Fast Market
REPLAY
7:00 pm
Next Gen Investing
REPLAY
education
8:00 pm
Your First Trade
REPLAY
8:30 pm
Trading 360
REPLAY
9:30 pm
Fast Market
REPLAY
10:30 pm
Next Gen Investing
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US